As the major anti-cancer immune cell types, PB- and TI-CD8 T cells exhibited different populations of effector/memory phenotypes (Supplementary Figs. 2b and  3e, f), all of which exhibited lower expression of BCL-XL relative to TI-Tregs (Supplementary Fig. 3g, h). This evidence concerns the gene CD8A and cancer.